PrognosDx Health and Accium BioSciences, Inc. Enter Into Collaborative and Research Agreement to Develop Clinical Tests Based on Histone Biomarkers

PALO ALTO, Calif.--(BUSINESS WIRE)--PrognosDx Health, a pioneering company in cancer epigenetics, announced today that Dr. Jeffrey L. Wolf has joined its scientific advisory board. An expert in multiple myeloma and other hematopoietic malignancies, Dr. Wolf also specializes in bone marrow transplantation for treatment of a variety of cancers. Dr. Wolf is the Director of the Multiple Myeloma Program in the Division of Hematology and Oncology at the Helen Diller Family Comprehensive Cancer Center and a Clinical Professor of Medicine at UCSF.